These emerging antibodies, including SHR-1701 and BR102, contribute to the expanding repertoire of potential anti-TGFβ × PD-L1 blockade therapies, promising novel therapeutic strategies for the complex landscape of cancer immunotherapy. The gene discussed is CD274; the disease is cancer.